Verici Dx Past Earnings Performance
Past criteria checks 0/6
Verici Dx has been growing earnings at an average annual rate of 4.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 22705.3% per year.
Key information
4.4%
Earnings growth rate
20.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 22,705.3% |
| Return on equity | -48.8% |
| Net Margin | -111.0% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Verici Dx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -5 | 8 | 0 |
| 31 Mar 24 | 3 | -7 | 8 | 0 |
| 31 Dec 23 | 1 | -9 | 9 | 0 |
| 30 Sep 23 | 1 | -10 | 9 | 0 |
| 30 Jun 23 | 0 | -11 | 10 | 0 |
| 31 Mar 23 | 0 | -11 | 10 | 0 |
| 31 Dec 22 | 0 | -11 | 10 | 0 |
| 30 Sep 22 | 0 | -11 | 10 | 0 |
| 30 Jun 22 | 0 | -11 | 10 | 0 |
| 31 Mar 22 | 0 | -10 | 8 | 0 |
| 31 Dec 21 | 0 | -8 | 7 | 0 |
Quality Earnings: 63V is currently unprofitable.
Growing Profit Margin: 63V is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 63V is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare 63V's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 63V is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 63V has a negative Return on Equity (-48.77%), as it is currently unprofitable.